Appointment of Director
Source: RNS
The Monks Investment Trust PLC (MNKS)
Appointment of Director
The Board is pleased to announce the appointment of Dr Dina Chaya as a non-executive Director of the Company, with an expected effective start date of 30 November 2022.
Dr Chaya is an Adviser to Omega Funds and a Partner with NeoMed Management. She currently serves on the board of directors of Anjarium Biosciences, Imago BioSciences, Oxular and Spruce Biosciences. Dr Chaya has been investing in the private equity and venture capital healthcare industry since 2001, having been previously at 3i in London and Index Ventures in Geneva.
She is a CFA charterholder and has a Ph.D. degree in Molecular and Cellular Biology of Development from Paris VI University and carried out postdoctoral research at Brown University, Providence, and at the Fox Chase Cancer Centre, Philadelphia.
The Chairman of Monks, Karl Sternberg, said: "I am delighted that Dr Chaya has agreed to bring her healthcare expertise and investment experience to our Board."
The appointment of Dr Chaya is subject to ratification by shareholders at the Annual General Meeting of the Company to be held in 2023.
There is no further information required to be disclosed under Listing Rule 9.6.13.
Baillie Gifford & Co Limited
Managers and Secretaries
9 September 2022
Legal Entity Identifier: 213800MRI1JTUKG5AF64
Regulated Information Classification: Additional regulated information required to be disclosed under applicable law
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
